ALNY – alnylam pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
11/13
02:17 pm
alny
Low
Cell and Gene Therapy Market to Grow by USD 6.56 Billion (2024-2028), Driven by Rising Prevalence of Chronic Diseases, AI-Powered Report Explores Market Evolution - Technavio [Yahoo! Finance]
11/12
07:31 am
alny
Low
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was downgraded by analysts at Wolfe Research from a "peer perform" rating to an "underperform" rating.
11/12
05:39 am
alny
Low
Antisense & RNAi Therapeutics Market Overview 2024-2030 - Global Antisense & RNAi Therapeutics Market Forecast to Reach $14.4 Billion by 2030 [Yahoo! Finance]
11/8
10:10 am
alny
Low
RFK Jr. could play a big role under Trump—and Big Pharma is sounding the alarm: ‘We need somebody grounded by science and evidence, not somebody who rejects it' [Yahoo! Finance]
11/8
07:59 am
alny
Low
RFK Jr. could play a big role under Trump—and Big Pharma is sounding the alarm: ‘We need somebody grounded by science and evidence, not somebody who rejects it' [Fortune]
10/31/2024
08:00 am
alny
-0.2%
BEAT
8/1/2024
08:00 am
alny
12.5%
BEAT
5/2/2024
08:00 am
alny
-0.3%
BEAT
2/15/2024
08:00 am
alny
-10.2%
BEAT
11/12
07:31 am
Downgrades
Peer Perform
Underperform
Wolfe Research
Low
-1.8%
11/12
07:31 am
Downgrades
Peer Perform
Underperform
Wolfe Research
Low
-1.8%
11/12
05:19 am
Downgrades
Peer Perform
Underperform
Wolfe Research
Low
-2.2%
11/12
05:19 am
Downgrades
Peer Perform
Underperform
Wolfe Research
Low
-2.2%
11/4
08:19 am
Reiterates
Buy
Buy
HC Wainwright
Low
0.0%
11/12
09:51 am
alny
Low
Form SC 13G/A ALNYLAM PHARMACEUTICALS, Filed by: FMR LLC
11/8
10:35 am
alny
Low
Form SC 13G/A ALNYLAM PHARMACEUTICALS, Filed by: WELLINGTON MANAGEMENT GROUP LLP
10/31
08:23 am
alny
Low
Form 10-Q ALNYLAM PHARMACEUTICALS, For: Sep 30
10/31
08:11 am
alny
Low
Form 8-K ALNYLAM PHARMACEUTICALS, For: Oct 31
10/10
04:06 pm
alny
Low
Form 4 ALNYLAM PHARMACEUTICALS, For: Oct 08 Filed by: Garg Pushkal
Show more
Top News Gainers
8/6 Form 10-Q ALNYLAM PHARMACEUTICALS, For: Jun 30 11.4%
11/19 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $128.00 price target on the stock. 10.5%
3/12 Why Alnylam Pharmaceuticals, Intuitive Surgical, and ResMed Stocks Sank Today [The Motley Fool] 9.1%
8/6 Form 8-K ALNYLAM PHARMACEUTICALS, For: Aug 06 6.3%
4/6 Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs 6.0%
11/18 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $120.00 price target on the stock. 5.6%
11/22 Form 4 ALNYLAM PHARMACEUTICALS, For: Nov 20 Filed by: Greenstreet Yvonne 5.2%
10/31 Alnylam Pharmaceuticals, Inc. 2019 Q3 - Results - Earnings Call Presentation [Seeking Alpha] 4.9%
11/26 Alnylam to Webcast Presentations at Upcoming December Investor Conferences 4.9%
2/9 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $154.00 price target on the stock. 4.8%
Top News Decliners
12/17 Alnylam gene-silencing therapy to treat kidney disorder succeeds in late-stage study [Reuters (UK)] -11.7%
3/10 Alnylam Pharmaceuticals (ALNY) Presents At Barclays Global Healthcare Conference - Slideshow [Seeking Alpha] -6.9%
2/21 Form 4 ALNYLAM PHARMACEUTICALS, For: Feb 20 Filed by: MARAGANORE JOHN -6.7%
11/22 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Morgan Stanley from $124.00 to $141.00. They now have an "overweight" rating on the stock. -4.7%
4/13 Alnylam's stock surges after Blackstone confirms $2 billion investment [MarketWatch] -4.4%
9/26 Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference -4.3%
3/16 Alnylam shows wild action on a wild day [Seeking Alpha] -4.2%
5/3 Form SC 13G/A ALNYLAM PHARMACEUTICALS, Filed by: Sanofi -4.2%
9/6 Alnylam to Host Sixth Annual “RNAi Roundtable” Webcast Series -4.0%
1/10 Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1) -3.9%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3